Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 264

1.

Real-world burden of comorbidities in US patients with psoriatic arthritis.

Shah K, Paris M, Mellars L, Changolkar A, Mease PJ.

RMD Open. 2017 Dec 28;3(2):e000588. doi: 10.1136/rmdopen-2017-000588. eCollection 2017.

2.

Minimal Disease Activity among Active Psoriatic Arthritis Patients Treated with Secukinumab: 2-year Results from the FUTURE 2 Study.

Coates LC, Mease PJ, Gossec L, Kirkham B, Sherif B, Gaillez C, Mpofu S, Jugl SM, Karyekar C, Gandhi KK.

Arthritis Care Res (Hoboken). 2018 Feb 6. doi: 10.1002/acr.23537. [Epub ahead of print]

PMID:
29409133
3.

Characterization of Patients With Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis in the US-Based Corrona Registry.

Mease PJ, van der Heijde D, Karki C, Palmer JB, Liu M, Pandurengan R, Park Y, Greenberg JD.

Arthritis Care Res (Hoboken). 2018 Feb 6. doi: 10.1002/acr.23534. [Epub ahead of print]

PMID:
29409123
4.

Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1.

Coates LC, Kishimoto M, Gottlieb A, Shuler CL, Lin CY, Lee CH, Mease PJ.

RMD Open. 2017 Dec 22;3(2):e000567. doi: 10.1136/rmdopen-2017-000567. eCollection 2017.

5.

Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1).

van der Heijde D, Gladman DD, Kishimoto M, Okada M, Rathmann SS, Moriarty SR, Shuler CL, Carlier H, Benichou O, Mease PJ.

J Rheumatol. 2017 Dec 15. pii: jrheum.170429. doi: 10.3899/jrheum.170429. [Epub ahead of print]

6.

Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial.

Mease PJ, Kavanaugh A, Coates LC, McInnes IB, Hojnik M, Zhang Y, Anderson JK, Dorr AP, Gladman DD.

RMD Open. 2017 Jul 18;3(1):e000415. doi: 10.1136/rmdopen-2016-000415. eCollection 2017.

7.

CNTO6785, a Fully Human Antiinterleukin 17 Monoclonal Antibody, in Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: A Randomized, Placebo-controlled, Phase II, Dose-ranging Study.

Mease PJ, Jeka S, Jaller JJ, Kitumnuaypong T, Louthrenoo W, Mann H, Matsievskaia G, Soriano ER, Jia B, Wang C, Nie J, Hsia E.

J Rheumatol. 2018 Jan;45(1):22-31. doi: 10.3899/jrheum.161238. Epub 2017 Nov 1.

8.

Trial Characteristics as Contextual Factors when Evaluating Targeted Therapies in Patients with Psoriatic Disease: A Meta-Epidemiological Study.

Ballegaard C, Jørgensen TS, Skougaard M, Strand V, Mease PJ, Kristensen LE, Dreyer L, Gottlieb A, de Wit M, Christensen R, Tarp S.

Arthritis Care Res (Hoboken). 2017 Oct 26. doi: 10.1002/acr.23455. [Epub ahead of print]

PMID:
29073353
9.

Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study.

McInnes IB, Mease PJ, Ritchlin CT, Rahman P, Gottlieb AB, Kirkham B, Kajekar R, Delicha EM, Pricop L, Mpofu S.

Rheumatology (Oxford). 2017 Nov 1;56(11):1993-2003. doi: 10.1093/rheumatology/kex301.

PMID:
28968735
10.

GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies.

Tillett W, Orbai AM, Ogdie A, Leung YY, Strand V, Gladman DD, Mease PJ, Coates LC; GRAPPA OMERACT Psoriatic Arthritis working group.

Ann Rheum Dis. 2017 Jul 26. pii: annrheumdis-2017-212004. doi: 10.1136/annrheumdis-2017-212004. [Epub ahead of print] No abstract available.

PMID:
28747326
11.

Evaluation of the effect of baseline MRI sacroiliitis and C reactive protein status on etanercept treatment response in non-radiographic axial spondyloarthritis: a post hoc analysis of the EMBARK study.

Brown MA, Bird PA, Robinson PC, Mease PJ, Bosch FVD, Surian C, Jones H, Szumski A, Marshall L, Wiid Z, Dougados M.

Ann Rheum Dis. 2017 Jul 3. pii: annrheumdis-2017-211313. doi: 10.1136/annrheumdis-2017-211313. [Epub ahead of print] No abstract available.

PMID:
28673924
12.

Clinical and Patient-reported Outcomes in Patients with Psoriatic Arthritis (PsA) by Body Surface Area Affected by Psoriasis: Results from the Corrona PsA/Spondyloarthritis Registry.

Mease PJ, Karki C, Palmer JB, Etzel CJ, Kavanaugh A, Ritchlin CT, Malley W, Herrera V, Tran M, Greenberg JD.

J Rheumatol. 2017 Aug;44(8):1151-1158. doi: 10.3899/jrheum.160963. Epub 2017 Jun 15.

PMID:
28620063
13.

Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA.

van der Heijde D, Dougados M, Landewé R, Sieper J, Maksymowych WP, Rudwaleit M, Van den Bosch F, Braun J, Mease PJ, Kivitz AJ, Walsh J, Davies O, Bauer L, Hoepken B, Peterson L, Deodhar A.

Rheumatology (Oxford). 2017 Sep 1;56(9):1498-1509. doi: 10.1093/rheumatology/kex174.

PMID:
28498975
14.

Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis.

Mease PJ, Gottlieb AB, van der Heijde D, FitzGerald O, Johnsen A, Nys M, Banerjee S, Gladman DD.

Ann Rheum Dis. 2017 Sep;76(9):1550-1558. doi: 10.1136/annrheumdis-2016-210724. Epub 2017 May 4.

15.

GRAPPA 2016 Project Report.

Helliwell PS, FitzGerald O, Coates LC, Callis Duffin K, Mease PJ.

J Rheumatol. 2017 May;44(5):706-710. doi: 10.3899/jrheum.170153.

PMID:
28461534
16.

Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group.

Ogdie A, de Wit M, Callis Duffin K, Campbell W, Chau J, Coates LC, Eder L, Elmamoun M, FitzGerald O, Gladman DD, Goel N, James J, Kalyoncu U, Latella J, Lindsay C, Mease PJ, O'Sullivan D, Steinkoenig I, Strand V, Tillett W, Orbai AM.

J Rheumatol. 2017 May;44(5):697-700. doi: 10.3899/jrheum.170150.

PMID:
28461531
17.

International Treatment Recommendations Update: A Report from the GRAPPA 2016 Annual Meeting.

Coates LC, Chandran V, Ogdie A, O'Sullivan D, Brooke M, Steinkoenig I, Mease PJ, Ritchlin CT, Kavanaugh A.

J Rheumatol. 2017 May;44(5):684-685. doi: 10.3899/jrheum.170144.

PMID:
28461525
18.

Proceedings of the GRAPPA 2016 Retreat.

Jadon DR, Gladman DD, Mease PJ, FitzGerald O, Chandran V, Goel N, Rosen CF, Maksymowych WP, Ritchlin CT, Ogdie A, Coates LC, Cauli A, Soriano ER, Husni ME, Campbell W, Azevedo VF, Callis Duffin K, Armstrong AW, Gottlieb AB, Kavanaugh A, Garg A, Helliwell PS.

J Rheumatol. 2017 May;44(5):668-673. doi: 10.3899/jrheum.170141.

PMID:
28461522
19.

Fibromyalgia, a missed comorbidity in spondyloarthritis: prevalence and impact on assessment and treatment.

Mease PJ.

Curr Opin Rheumatol. 2017 Jul;29(4):304-310. doi: 10.1097/BOR.0000000000000388. Review.

PMID:
28394827
20.

Clinical Characteristics, Disease Activity, and Patient-Reported Outcomes in Psoriatic Arthritis Patients With Dactylitis or Enthesitis: Results From the Corrona Psoriatic Arthritis/Spondyloarthritis Registry.

Mease PJ, Karki C, Palmer JB, Etzel CJ, Kavanaugh A, Ritchlin CT, Malley W, Herrera V, Tran M, Greenberg JD.

Arthritis Care Res (Hoboken). 2017 Nov;69(11):1692-1699. doi: 10.1002/acr.23249.

PMID:
28376239
21.

Performance of 3 Enthesitis Indices in Patients with Peripheral Spondyloarthritis During Treatment with Adalimumab.

Mease PJ, Van den Bosch F, Sieper J, Xia Y, Pangan AL, Song IH.

J Rheumatol. 2017 May;44(5):599-608. doi: 10.3899/jrheum.160387. Epub 2017 Mar 15.

22.

Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016.

Orbai AM, de Wit M, Mease PJ, Callis Duffin K, Elmamoun M, Tillett W, Campbell W, FitzGerald O, Gladman DD, Goel N, Gossec L, Hoejgaard P, Leung YY, Lindsay C, Strand V, van der Heijde DM, Shea B, Christensen R, Coates L, Eder L, McHugh N, Kalyoncu U, Steinkoenig I, Ogdie A.

J Rheumatol. 2017 Oct;44(10):1522-1528. doi: 10.3899/jrheum.160904. Epub 2017 Feb 1.

23.

Societal costs and patients' experience of health inequities before and after diagnosis of psoriatic arthritis: a Danish cohort study.

Kristensen LE, Jørgensen TS, Christensen R, Gudbergsen H, Dreyer L, Ballegaard C, Jacobsson LTH, Strand V, Mease PJ, Kjellberg J.

Ann Rheum Dis. 2017 Sep;76(9):1495-1501. doi: 10.1136/annrheumdis-2016-210579. Epub 2017 Jan 30.

PMID:
28137915
24.

Changes in Treatment Patterns in Patients with Psoriatic Arthritis Initiating Biologic and Nonbiologic Therapy in a Clinical Registry.

Mease PJ, Lesperance T, Liu M, Collier DH, Mason M, Deveikis S, Accortt NA.

J Rheumatol. 2017 Feb;44(2):184-192. doi: 10.3899/jrheum.160343. Epub 2017 Jan 15.

PMID:
28089969
25.

2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria.

Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Häuser W, Katz RL, Mease PJ, Russell AS, Russell IJ, Walitt B.

Semin Arthritis Rheum. 2016 Dec;46(3):319-329. doi: 10.1016/j.semarthrit.2016.08.012. Epub 2016 Aug 30.

PMID:
27916278
26.

Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations.

Gossec L, Coates LC, de Wit M, Kavanaugh A, Ramiro S, Mease PJ, Ritchlin CT, van der Heijde D, Smolen JS.

Nat Rev Rheumatol. 2016 Dec;12(12):743-750. doi: 10.1038/nrrheum.2016.183. Epub 2016 Nov 10. Review.

PMID:
27829672
27.

Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group.

Fleischmann R, Mease PJ, Schwartzman S, Hwang LJ, Soma K, Connell CA, Takiya L, Bananis E.

Clin Rheumatol. 2017 Jan;36(1):15-24. doi: 10.1007/s10067-016-3436-1. Epub 2016 Oct 12.

28.

Secukinumab for Long-Term Treatment of Psoriatic Arthritis: A Two-Year Followup From a Phase III, Randomized, Double-Blind Placebo-Controlled Study.

Kavanaugh A, Mease PJ, Reimold AM, Tahir H, Rech J, Hall S, Geusens P, Wang Z, Pricop L, Mpofu S; FUTURE-1 Study Group.

Arthritis Care Res (Hoboken). 2017 Mar;69(3):347-355. doi: 10.1002/acr.23111.

PMID:
27696786
29.

Early Disease Activity or Clinical Response as Predictors of Long-Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis.

van der Heijde D, Deodhar A, Fleischmann R, Mease PJ, Rudwaleit M, Nurminen T, Davies O.

Arthritis Care Res (Hoboken). 2017 Jul;69(7):1030-1039. doi: 10.1002/acr.23092. Epub 2017 Jun 2.

30.

The unmet need in rheumatology: reports from the Targeted Therapies meeting 2016.

Winthrop KL, Strand V, van der Heijde DM, Mease PJ, Crow MK, Weinblatt M, Bathon JM, Buch MH, Burmester GR, Dougados M, Kay J, Mariette X, Breedveld FC, Kalden JR, Smolen JS, Furst DE.

Clin Exp Rheumatol. 2016 Jul-Aug;34(4 Suppl 98):69-76. Epub 2016 Aug 3.

31.

Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.

Mease PJ, van der Heijde D, Ritchlin CT, Okada M, Cuchacovich RS, Shuler CL, Lin CY, Braun DK, Lee CH, Gladman DD; SPIRIT-P1 Study Group.

Ann Rheum Dis. 2017 Jan;76(1):79-87. doi: 10.1136/annrheumdis-2016-209709. Epub 2016 Aug 23.

32.

Blood-Borne RNA Correlates with Disease Activity and IFN-Stimulated Gene Expression in Systemic Lupus Erythematosus.

Doedens JR, Jones WD, Hill K, Mason MJ, Gersuk VH, Mease PJ, Dall'Era M, Aranow C, Martin RW, Cohen SB, Fleischmann RM, Kivitz AJ, Burge DJ, Chaussabel D, Elkon KB, Posada JA.

J Immunol. 2016 Oct 1;197(7):2854-63. doi: 10.4049/jimmunol.1601142. Epub 2016 Aug 17.

33.

Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study.

Kavanaugh A, McInnes IB, Mease PJ, Hall S, Chinoy H, Kivitz AJ, Wang Z, Mpofu S.

J Rheumatol. 2016 Sep;43(9):1713-7. doi: 10.3899/jrheum.160275. Epub 2016 Jun 15.

34.

Presidential Round Table: A Report from the GRAPPA Annual Meeting.

Gladman DD, Mease PJ, Boehncke WH, Helliwell PS, Callis Duffin K.

J Rheumatol. 2016 May;43(5):986-9. doi: 10.3899/jrheum.160120.

PMID:
27134275
35.

GRAPPA 2015 Research and Education Project Reports.

Mease PJ, Helliwell PS, Boehncke WH, Coates LC, FitzGerald O, Gladman DD, Deodhar AA, Callis Duffin K.

J Rheumatol. 2016 May;43(5):979-85. doi: 10.3899/jrheum.160119.

PMID:
27134274
36.

Report of the GRAPPA-OMERACT Psoriatic Arthritis Working Group from the GRAPPA 2015 Annual Meeting.

Orbai AM, Mease PJ, de Wit M, Kalyoncu U, Campbell W, Tillett W, Eder L, Elmamoun M, FitzGerald O, Gladman DD, Goel N, Gossec L, Lindsay CA, Steinkoenig I, Helliwell PS, McHugh NJ, Strand V, Ogdie A.

J Rheumatol. 2016 May;43(5):965-9. doi: 10.3899/jrheum.160116.

37.

The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis.

Mease PJ, Gottlieb AB, Berman A, Drescher E, Xing J, Wong R, Banerjee S.

Arthritis Rheumatol. 2016 Sep;68(9):2163-73. doi: 10.1002/art.39700.

38.

Ms. A.M. Taylor, et al reply.

Taylor AM, Taylor JO, Singh JA, Conaghan PG, Choy EH, Tugwell PS, Kaiser U, Strand V, Simon LS, Mease PJ.

J Rheumatol. 2016 Apr;43(4):826. doi: 10.3899/jrheum.151456. No abstract available.

PMID:
27037244
39.

Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis.

van der Heijde D, Landewé RB, Mease PJ, McInnes IB, Conaghan PG, Pricop L, Ligozio G, Richards HB, Mpofu S.

Arthritis Rheumatol. 2016 Aug;68(8):1914-21. doi: 10.1002/art.39685.

40.
41.

Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registry.

Mease PJ, Collier DH, Saunders KC, Li G, Kremer JM, Greenberg JD.

RMD Open. 2015 Dec 30;1(1):e000181. doi: 10.1136/rmdopen-2015-000181. eCollection 2015.

42.

Frequency of Axial Spondyloarthritis Diagnosis Among Patients Seen by US Rheumatologists for Evaluation of Chronic Back Pain.

Deodhar A, Mease PJ, Reveille JD, Curtis JR, Chen S, Malhotra K, Pangan AL.

Arthritis Rheumatol. 2016 Jul;68(7):1669-76. doi: 10.1002/art.39612.

43.

Improvement in Psoriasis Signs and Symptoms Assessed by the Psoriasis Symptom Inventory with Brodalumab Treatment in Patients with Psoriatic Arthritis.

Mease PJ, Genovese MC, Mutebi A, Viswanathan HN, Chau D, Feng J, Erondu N, Nirula A.

J Rheumatol. 2016 Feb;43(2):343-9. doi: 10.3899/jrheum.150182. Epub 2016 Jan 15.

PMID:
26773108
44.

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis.

Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Laura Acosta-Felquer M, Armstrong AW, Bautista-Molano W, Boehncke WH, Campbell W, Cauli A, Espinoza LR, FitzGerald O, Gladman DD, Gottlieb A, Helliwell PS, Husni ME, Love TJ, Lubrano E, McHugh N, Nash P, Ogdie A, Orbai AM, Parkinson A, O'Sullivan D, Rosen CF, Schwartzman S, Siegel EL, Toloza S, Tuong W, Ritchlin CT.

Arthritis Rheumatol. 2016 May;68(5):1060-71. doi: 10.1002/art.39573. Epub 2016 Mar 23.

45.

Effectiveness and Feasibility Associated with Switching to a Second or Third TNF Inhibitor in Patients with Psoriatic Arthritis: A Cohort Study from Southern Sweden.

Kristensen LE, Lie E, Jacobsson LT, Christensen R, Mease PJ, Bliddal H, Geborek P.

J Rheumatol. 2016 Jan;43(1):81-7. doi: 10.3899/jrheum.150744. Epub 2015 Dec 1.

PMID:
26628604
46.

Genome-wide Association Analysis of Psoriatic Arthritis and Cutaneous Psoriasis Reveals Differences in Their Genetic Architecture.

Stuart PE, Nair RP, Tsoi LC, Tejasvi T, Das S, Kang HM, Ellinghaus E, Chandran V, Callis-Duffin K, Ike R, Li Y, Wen X, Enerbäck C, Gudjonsson JE, Kõks S, Kingo K, Esko T, Mrowietz U, Reis A, Wichmann HE, Gieger C, Hoffmann P, Nöthen MM, Winkelmann J, Kunz M, Moreta EG, Mease PJ, Ritchlin CT, Bowcock AM, Krueger GG, Lim HW, Weidinger S, Weichenthal M, Voorhees JJ, Rahman P, Gregersen PK, Franke A, Gladman DD, Abecasis GR, Elder JT.

Am J Hum Genet. 2015 Dec 3;97(6):816-36. doi: 10.1016/j.ajhg.2015.10.019. Epub 2015 Nov 28.

47.

Clinical Responses in Joint and Skin Outcomes and Patient-Reported Outcomes are Associated with Increased Productivity in the Workplace and at Home in Psoriatic Arthritis Patients Treated with Certolizumab Pegol.

Kavanaugh A, Gladman D, van der Heijde D, Purcaru O, Mease PJ.

Value Health. 2015 Nov;18(7):A654. doi: 10.1016/j.jval.2015.09.2359. Epub 2015 Oct 20. No abstract available.

48.

Validation of the OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Score (PsAMRIS) for the Hand and Foot in a Randomized Placebo-controlled Trial.

Glinatsi D, Bird P, Gandjbakhch F, Mease PJ, Bøyesen P, Peterfy CG, Conaghan PG, Østergaard M.

J Rheumatol. 2015 Dec;42(12):2473-9. doi: 10.3899/jrheum.141010. Epub 2015 Nov 1.

PMID:
26523032
49.

Biologic Therapy for Psoriatic Arthritis.

Mease PJ.

Rheum Dis Clin North Am. 2015 Nov;41(4):723-38. doi: 10.1016/j.rdc.2015.07.010. Epub 2015 Sep 7. Review.

PMID:
26476229
50.

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.

Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, Landewé R, Nash P, Pricop L, Yuan J, Richards HB, Mpofu S; FUTURE 1 Study Group.

N Engl J Med. 2015 Oct;373(14):1329-39. doi: 10.1056/NEJMoa1412679.

Supplemental Content

Loading ...
Support Center